Hypercalcemia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 2 PAGES: 26

More Info
									Hypercalcemia – Pipeline Review, H1 2012




                    Hypercalcemia – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1686IDB
                                                                                            Publication Date: January 2012




Hypercalcemia – Pipeline Review, H1 2012                                                   GMDHC1686IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Hypercalcemia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 3
Introduction......................................................................................................................................................................................... 4
    Global Markets Direct Report Coverage ........................................................................................................................................ 4
Hypercalcemia Overview .................................................................................................................................................................... 5
Therapeutics Development................................................................................................................................................................. 6
    An Overview of Pipeline Products for Hypercalcemia.................................................................................................................... 6
Hypercalcemia Therapeutics under Development by Companies ...................................................................................................... 8
Hypercalcemia Therapeutics under Investigation by Universities/Institutes ....................................................................................... 9
Early Clinical Stage Products ........................................................................................................................................................... 10
    Comparative Analysis .................................................................................................................................................................. 10
Hypercalcemia Therapeutics – Products under Development by Companies .................................................................................. 11
Hypercalcemia Therapeutics – Products under Investigation by Universities/Institutes ................................................................... 12
Companies Involved in Hypercalcemia Therapeutics Development ................................................................................................. 13
    Genta Incorporated...................................................................................................................................................................... 13
Hypercalcemia – Therapeutics Assessment..................................................................................................................................... 14
    Assessment by Monotherapy Products ....................................................................................................................................... 14
    Assessment by Route of Administration ...................................................................................................................................... 15
    Assessment by Molecule Type .................................................................................................................................................... 17
Drug Profiles..................................................................................................................................................................................... 19
    G4544 - Drug Profile.................................................................................................................................................................... 19
         Product Description................................................................................................................................................................. 19
         Mechanism of Action ............................................................................................................................................................... 19
         R&D Progress ......................................................................................................................................................................... 19
    Cholecalciferol - Drug Profile ....................................................................................................................................................... 21
         Product Description................................................................................................................................................................. 21
         Mechanism of Action ............................................................................................................................................................... 21
         R&D Progress ........................................................................................................
								
To top